Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Germaphobix
WARNING LETTER
•Germaphobix•January 1, 2026

Germaphobix – FDA Warning Letter, Jan 1, 2026

Record Details

The FDA issued a Warning Letter to Germaphobix on January 09, 2026, following a review of the company"s website (last visited January 2026) and prior communications. The letter addresses Germaphobix"s unauthorized marketing and distribution of a human immunodeficiency virus (HIV) serological diagnostic dried blood spot (DBS) card self-collection kit. The FDA determined that this kit is an unapproved medical device under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The primary violations include the kit being considered adulterated, as it lacks an approved premarket approval application or an investigational device exemption. It is also deemed misbranded because the required notification of intent to introduce the device into commercial distribution was not provided to the agency. Germaphobix had previously argued the kits were Lab-Developed Tests, but the FDA clarified that these self-collection kits require formal marketing authorization.

The FDA expressed concerns regarding the kit"s safety and effectiveness due to the absence of appropriate testing, data review, and authorization, noting potential issues with safe specimen collection, shipping integrity, and sample stability. Germaphobix is mandated to immediately cease all activities that result in the misbranding or adulteration of the HIV DBS card self-collection kit. The company must provide a written response to the FDA within fifteen working days, detailing the specific corrective actions taken to address these violations and prevent recurrence. Non-compliance may result in further regulatory actions.

Company
Germaphobix
Inspection date
January 1, 2026
Product type
Biologics
Office
Center for Biologics Evaluation and Research
People
  • Melissa J. Mendoza (Director)
  • Jon Tavarez
View Company Profile

ID · 0cf39f0a-3839-4795-8121-ca9f38ed6da2

Violation Codes10
FD&C Act 201(h)(1)21 U.S.C. 321(h)(1)FD&C Act 501(f)(1)(B)21 U.S.C. 351(f)(1)(B)FD&C Act 515(a)21 U.S.C. 360e(a)FD&C Act 520(g)21 U.S.C. 360j(g)FD&C Act 502(o)21 U.S.C. 352(o)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Germaphobix
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.